Ingalls & Snyder LLC’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.6M Buy
730,345
+22,248
+3% +$582K 0.48% 43
2026
Q1
$19.9M Sell
708,097
-9,885
-1% -$263K 0.7% 34
2025
Q4
$17.9M Sell
717,982
-16,829
-2% -$424K 0.66% 37
2025
Q3
$18.7M Sell
734,811
-20,502
-3% -$506K 0.61% 32
2025
Q2
$18.3M Buy
755,313
+110,393
+17% +$2.57M 0.65% 30
2025
Q1
$16.3M Buy
644,920
+2,815
+0.4% +$73.7K 0.54% 33
2024
Q4
$17M Buy
642,105
+20,666
+3% +$561K 0.67% 36
2024
Q3
$18M Sell
621,439
-395
-0.1% -$11.5K 0.7% 33
2024
Q2
$17.4M Sell
621,834
-1,098
-0.2% -$30.2K 0.75% 34
2024
Q1
$17.3M Buy
622,932
+46,130
+8% +$1.28M 0.76% 36
2023
Q4
$16.6M Sell
576,802
-25,951
-4% -$784K 0.75% 32
2023
Q3
$20M Buy
602,753
+4,103
+0.7% +$145K 0.96% 25
2023
Q2
$22M Buy
598,650
+718
+0.1% +$27.9K 1.05% 24
2023
Q1
$24.4M Buy
597,932
+16,737
+3% +$723K 1.25% 17
2022
Q4
$29.8M Sell
581,195
-59
-0% -$2.83K 1.62% 13
2022
Q3
$25.4M Sell
581,254
-1,243
-0.2% -$60.4K 1.42% 12
2022
Q2
$30.5M Sell
582,497
-2,046
-0.4% -$104K 1.6% 11
2022
Q1
$30.3M Buy
584,543
+4,828
+0.8% +$251K 1.35% 15
2021
Q4
$34.2M Buy
579,715
+2,766
+0.5% +$137K 1.54% 12
2021
Q3
$24.8M Sell
576,949
-19,450
-3% -$862K 1.14% 20
2021
Q2
$23.4M Sell
596,399
-5,586
-0.9% -$217K 1.04% 24
2021
Q1
$21.8M Sell
601,985
-7,371
-1% -$262K 1.02% 25
2020
Q4
$22.4M Sell
609,356
-42,439
-7% -$1.56M 1.11% 21
2020
Q3
$22.7M Buy
651,795
+10,740
+2% +$377K 1.56% 15
2020
Q2
$19.9M Sell
641,055
-5,358
-0.8% -$182K 1.14% 21
2020
Q1
$20M Sell
646,413
-2,453
-0.4% -$83.6K 1.35% 14
2019
Q4
$24.1M Buy
648,866
+5,431
+0.8% +$193K 1.31% 18
2019
Q3
$21.9M Sell
643,435
-9,436
-1% -$343K 1.07% 19
2019
Q2
$26.8M Buy
652,871
+1,156
+0.2% +$45.9K 1.29% 14
2019
Q1
$26.3M Sell
651,715
-5,014
-0.8% -$201K 1.25% 14
2018
Q4
$27.2M Sell
656,729
-12,905
-2% -$536K 1.44% 11
2018
Q3
$28M Buy
669,634
+1,827
+0.3% +$70.3K 1.18% 15
2018
Q2
$23M Buy
667,807
+5,611
+0.8% +$192K 1.07% 16
2018
Q1
$22.3M Buy
662,196
+3,621
+0.5% +$124K 1.09% 21
2017
Q4
$22.6M Buy
658,575
+2,037
+0.3% +$69.5K 1.04% 20
2017
Q3
$22.2M Sell
656,538
-216,507
-25% -$6.96M 1.16% 18
2017
Q2
$27.8M Buy
873,045
+4,436
+0.5% +$140K 1.51% 12
2017
Q1
$28.2M Buy
868,609
+604
+0.1% +$19K 1.5% 12
2016
Q4
$26.7M Sell
868,005
-7,429
-0.8% -$227K 1.46% 15
2016
Q3
$28.1M Sell
875,434
-4,114
-0.5% -$138K 1.57% 14
2016
Q2
$29.4M Sell
879,548
-8,816
-1% -$281K 1.73% 11
2016
Q1
$25M Sell
888,364
-8,776
-1% -$251K 1.59% 14
2015
Q4
$27.5M Sell
897,140
-10,912
-1% -$343K 1.76% 12
2015
Q3
$27.1M Buy
908,052
+7,313
+0.8% +$234K 1.77% 10
2015
Q2
$28.7M Sell
900,739
-10,101
-1% -$329K 1.58% 14
2015
Q1
$30.1M Sell
910,840
-1,096
-0.1% -$34.8K 1.66% 12
2014
Q4
$27M Sell
911,936
-3,935
-0.4% -$113K 1.56% 16
2014
Q3
$25.7M Sell
915,871
-600
-0.1% -$16.8K 1.38% 17
2014
Q2
$25.8M Buy
916,471
+1,871
+0.2% +$53.3K 1.27% 19
2014
Q1
$27.9M Sell
914,600
-15,379
-2% -$459K 1.49% 16
2013
Q4
$27M Sell
929,979
-1,475
-0.2% -$42.9K 1.49% 15
2013
Q3
$25.4M Sell
931,454
-4,060
-0.4% -$110K 1.52% 14
2013
Q2
$24.9M Buy
+935,514
New +$25.8M 1.58% 14

Other funds holding PFE

Ingalls & Snyder LLC's PFE Position: Q2 2026 in Review

Ingalls & Snyder LLC increased its Pfizer (PFE) stake by 3.1% in Q2 2026, buying an estimated $582K and bringing the position to 730,345 shares worth $17.6M. The position accounts for 0.48% of the portfolio, ranked #43.

Ingalls & Snyder LLC first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $34.2M in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Ingalls & Snyder LLC held 730,345 shares of Pfizer worth $17.6M as of Q2 2026.
  • Ingalls & Snyder LLC bought 22,248 Pfizer shares in Q2 2026, an estimated $582K.
  • Pfizer made up 0.48% of Ingalls & Snyder LLC's portfolio in Q2 2026, its #43 holding.
  • Ingalls & Snyder LLC first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Ingalls & Snyder LLC's Pfizer position peaked at $34.2M in Q4 2021.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2026, filed 14 Aug 2026.